Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)’s Intellia Therapeutics NTLA Stock Holding History

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$677K	Hold	40,000	–	–	0.27%	98
2026 Q1	$513K	Hold	40,000	–	–	0.26%	84
2025 Q4	$360K	Sell	40,000 -40,000	-50%	-$551K	0.18%	90
2025 Q3	$1.38M	Sell	80,000 -20,000	-20%	-$246K	0.73%	45
2025 Q2	$938K	Buy	100,000 +19,000	+23%	+$156K	0.49%	60
2025 Q1	$576K	Buy	81,000 +19,000	+31%	+$192K	0.37%	73
2024 Q4	$723K	Buy	62,000 +27,000	+77%	+$421K	0.42%	68
2024 Q3	$719K	Buy	35,000 +2,000	+6%	+$46.1K	0.46%	66
2024 Q2	$739K	Buy	33,000 +6,000	+22%	+$143K	0.48%	62
2024 Q1	$743K	Buy	27,000 +6,000	+29%	+$167K	0.51%	63
2023 Q4	$640K	Hold	21,000	–	–	0.53%	62
2023 Q3	$640K	Buy	21,000 +10,000	+91%	+$388K	0.53%	62
2023 Q2	$449K	Buy	11,000 +2,000	+22%	+$81.1K	0.39%	72
2023 Q1	$335K	Buy	+9,000	New	+$353K	0.35%	73

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s NTLA Position: Q2 2026 in Review

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 40,000 shares worth $677K. The position accounts for 0.27% of the portfolio, ranked #98.

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) first reported a position in NTLA in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.38M in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) held 40,000 shares of Intellia Therapeutics worth $677K as of Q2 2026.
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up 0.27% of Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s portfolio in Q2 2026, its #98 holding.
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) first reported a position in Intellia Therapeutics in Q1 2023 and has held it in 14 quarters since.
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s Intellia Therapeutics position peaked at $1.38M in Q3 2025.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s 13F filing for Q2 2026, filed 22 Jul 2026.